Chlamydia trachomatis, miscellaneous sources-8270

December 2, 2021

Due to instrument issues at Mayo Clinic Laboratories (MCL), testing of this assay is currenlty delayed. Samples submitted will be stabilized in the testing laboratory at MCL.

Test info

Chlamydia trachomatis, miscellaneous sources
Chlamydia trachomatis DNA Probe
Chlamydia trachomatis RNA amplification

Chlamydia trachomatis


Detection of Chlamydia trachomatis in non-FDA-approved specimen types


Eye/ocular swab
  1. Swab the site using Aptima Multitest swab specimen collection kit swab.
    Note: The white swab provided within the collection kit is a cleaning swab and should not be used for collection. Discard the white cleaning swab.
  2. Place swab in transport tube provided in collection kit.
  3. Snap off swab at score line so swab fits into closed tube.
  4. Cap tube securely
  5. Label tube with patient's entire name, and date and time of collection.



Aptima Unisex swab specimen collection kit 


Peritoneal fluid (pelvic wash, cul-de-sac fluid)
  1. Transfer 1.0 mL specimen into the Aptima Specimen transfer tube (Mayo T652) within 24 hours of collection
  2. Cap tube securely
  3. Label tube with patient's entire name, 2nd unique identifier and date and time of collection

Eye/ocular swab:

Ambient (preferred) - 60 days

Refrigerated - 60 days

Frozen - 365 days


Peritoneal fluid:

Ambient (preferred) - 14 days

Refrigerated - 30 days

Frozen - 365 days


All specimens will be evaluated at Mayo Clinic Laboratories for test suitability


Mayo Clinic Laboratories (MCRNA): R-MM
Mo - Sa
1 - 3 days

Transcription Mediated Amplification

Clinical and Interpretive info





  • This report is intended for use in clinical monitoring or management of patients; it is not intended for use in medico-legal applications.
  • Appropriate specimen collection and handling is necessary for optimal assay performance.
  • Results should be interpreted in conjunction with other laboratory and clinical information.
  • A negative test result does not exclude the possibility of infection. Improper specimen collection, concurrent antibiotic therapy, presence of inhibitors, or low numbers of organisms in the specimen (ie, below the sensitivity of the test) may cause false-negative test results.
  • In low-prevalence populations, positive results must be interpreted carefully as false-positive results may occur more frequently than true-positive results in this setting.
  • In general, this assay should not be used to assess therapeutic success or failure, since nucleic acids from these organisms may persist for 3 weeks or more following antimicrobial therapy.
  • No interference is expected with swab specimens due to blood or lubricants and spermicides.
  • This assay does not detect Chlamydia pneumoniae.


  • A positive result indicates that rRNA of Chlamydia trachomatis  is present in the specimen tested and strongly supports a diagnosis of chlamydial infection.
  •  A negative result indicates that rRNA for C trachomatis was not detected in the specimen.
  •  The predictive value of an assay depends on the prevalence of the disease in any particular population. In settings with a high prevalence of sexually transmitted disease, positive assay results have a high likelihood of being true positives. In settings with a low prevalence of sexually transmitted disease, or in any setting in which a patient's clinical signs and symptoms or risk factors are inconsistent with gonococcal or chlamydial urogenital infection, positive results should be carefully assessed and the patient retested by other methods (eg, culture for N gonorrhoeae), if appropriate.
  • A negative result does not exclude the possibility of infection. If clinical indications strongly suggest chlamydial infection, additional specimens should be collected for testing. A result of indeterminate indicates that a new specimen should be collected